包含1个LEM域作为三阴性乳腺癌的新瘤基因和治疗点
Xiangling Li1,2, Shilong Jiang3, Ting Jiang1
1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Cancers
|June 10, 2023
概括
在三阴性乳腺癌 (TNBC) 中,LEMD1的表达很高,导致生存率低下. 向LEMD1有望改善TNBC治疗和化疗疗效率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一个重大的临床挑战,因为治疗选择有限,患者的生存率不佳.
- 确定新的治疗点对于推进TNBC治疗策略至关重要.
研究的目的:
- 研究含有1 (LEMD1) 的LEM域作为三阴性乳腺癌中潜在的治疗点的作用.
- 阐明LEMD1影响TNBC进展和患者结果的机制.
主要方法:
- 公共数据库和患者样本的生物信息分析,以评估TNBC中的LEMD1表达.
- 试验室研究涉及LEMD1沉默,以评估其对TNBC细胞增殖和迁移的影响.
- 在体内进行瘤形成测试和化学敏感性测试,以评估向LEMD1.1的治疗潜力.
主要成果:
- 发现LEMD1在TNBC组织中表达高,与患者存活时间减少相关.
- 抑制LEMD1显著抑制了TNBC细胞的增殖,迁移和体内瘤生长.
- 抑制LEMD1增加了TNBC细胞对帕克利塔塞尔化疗的敏感性.
- 通过激活ERK信号通路,LEMD1促进了TNBC的进展.
结论:
- 在三阴性乳腺癌中,LEMD1作为一种新瘤基因起作用.
- 向LEMD1代表了一种有希望的治疗策略,以改善TNBC的治疗结果和提高化疗疗效率.
相关概念视频
lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Receptor Tyrosine Kinases
13.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.2K


